- Home
- CURV vs CAPR Comparison
CURV vs CAPR Comparison
Compare CURV & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- CAPR
- Stock Information
- Founded
- CURV 2001
- CAPR 2005
- Country
- CURV United States
- CAPR United States
- Employees
- CURV N/A
- CAPR N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURV Consumer Discretionary
- CAPR Health Care
- Exchange
- CURV Nasdaq
- CAPR Nasdaq
- Market Cap
- CURV 215.9M
- CAPR 324.6M
- IPO Year
- CURV 2021
- CAPR N/A
- Fundamental
- Price
- CURV $2.16
- CAPR $6.28
- Analyst Decision
- CURV Hold
- CAPR Strong Buy
- Analyst Count
- CURV 4
- CAPR 8
- Target Price
- CURV $4.00
- CAPR $24.75
- AVG Volume (30 Days)
- CURV 482.6K
- CAPR 1.4M
- Earning Date
- CURV 09-04-2025
- CAPR 08-11-2025
- Dividend Yield
- CURV N/A
- CAPR N/A
- EPS Growth
- CURV N/A
- CAPR N/A
- EPS
- CURV 0.09
- CAPR N/A
- Revenue
- CURV $1,089,931,000.00
- CAPR $13,392,150.00
- Revenue This Year
- CURV N/A
- CAPR N/A
- Revenue Next Year
- CURV N/A
- CAPR $6,061.53
- P/E Ratio
- CURV $24.08
- CAPR N/A
- Revenue Growth
- CURV N/A
- CAPR N/A
- 52 Week Low
- CURV $2.08
- CAPR $3.98
- 52 Week High
- CURV $7.25
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- CURV 35.39
- CAPR 36.33
- Support Level
- CURV $2.13
- CAPR $6.17
- Resistance Level
- CURV $2.24
- CAPR $7.30
- Average True Range (ATR)
- CURV 0.10
- CAPR 0.43
- MACD
- CURV 0.05
- CAPR -0.11
- Stochastic Oscillator
- CURV 38.30
- CAPR 4.53
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.